Navigation Links
Codexis Names David Anton VP Bioindustrials R&D
Date:3/25/2008

REDWOOD CITY, Calif., March 25 /PRNewswire/ -- Codexis, Inc., today announced the appointment of David Anton, Ph.D. to the newly-created position of Vice President, Bioindustrials Research and Development. He joins Codexis from DuPont, where he was Venture Manager, Biofuels. He will report to Alan Shaw, Ph.D., President and CEO.

"Codexis targets major global energy and environmental markets where clean technology can make a significant impact," said Alan Shaw, Ph.D., President and CEO. "We are currently working with Shell in the development of biofuels, and expect to apply our technology to other potential new bioindustrial applications, such as carbon capture and storage, waste water purification and cleaner chemical manufacturing."

"Dr. Anton has over 25 years experience directing the development of new technology solutions and production processes at one of the world's largest science companies," Dr. Shaw added. "His experience as a scientist and venture manager in bioindustrials can make an important, immediate contribution to this important Codexis business. We are pleased to expand our management team with such a well known and broadly-experienced research executive."

Dr. Anton joined DuPont in 1983 and held a variety of senior research management positions across bioprocessing and biocatalysis. He led the process research, development and commercialization of several products, including 1,3 propanediol (a chemical intermediate used in a variety of industrial applications ranging from airplane deicing fluids to textiles and carpet). As Vice President, Research and Development for DuPont's joint venture with Tate and Lyle, he directed technology start-up activities for the first 100 million-pound plant for 1,3 propanediol, commissioned in Loudon, TN in 2006. As Venture Manager, Biofuels, he was global business lead for development of DuPont's advanced biofuel, biobutanol.

He holds a bachelor's degree in biochemistry from the University of California, Berkeley, and a Ph.D. in biochemistry from the University of Minnesota. He is a member of the joint DOE/USDA Biomass Research and Development Technology Advisory Committee.

Codexis, Inc., a clean technology company, is a leading developer of biocatalytic process technologies that can substantially reduce the cost of manufacturing across a broad range of industries. These technologies enable novel solutions for efficient, cost-effective and environmentally-friendly processes for pharmaceutical, energy and industrial chemical applications. In 2006, the U.S. EPA recognized Codexis with a Presidential Green Chemistry Challenge Award. Codexis is a registered trademark of Codexis, Inc. For more information, please visit http://www.codexis.com.

Contact: Justin Jackson, jjackson@burnsmc.com, Burns McClellan, 212-213-0006, or Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144.


'/>"/>
SOURCE Codexis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Codexis Launches Codex(TM) MicroCyp Platform to Produce Drug Metabolites and Novel Lead Compounds
2. Rothwell, Wolf Elected to Codexis Board
3. Codexis Opens Singapore Laboratory
4. Bruce Pasternack Elected to Codexis Board
5. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
6. Codexis Appoints Singapore Laboratories Managing Director
7. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors
8. Cato Research Names John Cline as President
9. Pathway Medical Technologies Names Paul Buckman Chairman of the Board of Directors
10. Onyx Pharmaceuticals Names N. Anthony Coles, M.D. as President, Chief Executive Officer and Member of its Board of Directors
11. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... 2016 On Wednesday, June 22, 2016, ... 0.22%; the Dow Jones Industrial Average edged 0.27% lower to ... down 0.17%. Stock-Callers.com has initiated coverage on the following equities: ... (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing their ...
(Date:6/23/2016)... ... 23, 2016 , ... Velocity Products, a division of Morris ... optimized exclusively for Okuma CNC machining centers at The International Manufacturing Technology Show, ... several companies with expertise in toolholding, cutting tools, machining dynamics and distribution, Velocity ...
(Date:6/22/2016)... Cell Applications, Inc. and StemoniX announced ... up to one billion human induced pluripotent stem ... These high-quality, consistent stem cells enable researchers to ... more time doing meaningful, relevant research. This achievement ... process that produces affordable, reliable HiPSC for life ...
Breaking Biology Technology:
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
Breaking Biology News(10 mins):